| WB | 1/500 - 1/2000 | Human,Mouse,Monkey |
| IF | 咨询技术 | Human,Mouse,Monkey |
| IHC | 1/200 - 1/1000 | Human,Mouse,Monkey |
| ICC | 技术咨询 | Human,Mouse,Monkey |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey |
| Elisa | 1/10000 | Human,Mouse,Monkey |
| Aliases | TPT; HHG1; HLP3; HPE3; SMMCI; TPTPS; MCOPCB5 |
| Entrez GeneID | 6469 |
| clone | 5H4 |
| WB Predicted band size | 49.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of human SHH (AA: 26-161) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于SHH抗体的3篇参考文献(信息为模拟示例，实际文献需自行验证)：
1. **文献名称**：*Targeting Sonic Hedgehog Signaling with Novel Antibodies in Cancer Therapy*
**作者**：Smith A, et al.
**摘要**：研究开发了高特异性SHH单克隆抗体，通过阻断SHH与PTCH1受体结合抑制肿瘤生长，在小鼠模型中显著减少胰腺癌和基底细胞癌的进展，为靶向治疗提供新策略。
2. **文献名称**：*SHH Antibody-Based Detection of Neural Tube Defects in Early Embryogenesis*
**作者**：Chen L, et al.
**摘要**：利用SHH多克隆抗体检测胚胎发育中SHH蛋白表达异常，发现其与神经管闭合缺陷相关，为产前筛查提供分子标志物。
3. **文献名称**：*A Novel SHH Neutralizing Antibody Reverses Chemoresistance in Glioblastoma*
**作者**：Wang Y, et al.
**摘要**：报道一种中和性SHH抗体可阻断肿瘤干细胞中SHH通路激活，增强化疗药物敏感性，在胶质母细胞瘤模型中显著延长生存期。
(注：以上为模拟内容，建议通过PubMed或Google Scholar以“SHH antibody”或“Sonic Hedgehog antibody”为关键词搜索最新文献。)
Sonic Hedgehog (SHH) antibodies are tools designed to target the SHH protein, a key morphogen in the Hedgehog (Hh) signaling pathway. This pathway is evolutionarily conserved and plays critical roles in embryonic development, tissue patterning, and stem cell regulation. SHH, secreted by cells, binds to the Patched (PTCH) receptor, relieving its inhibition on Smoothened (SMO) and activating downstream Gli transcription factors. Dysregulation of SHH signaling is linked to developmental disorders, cancers (e.g., medulloblastoma, basal cell carcinoma), and degenerative diseases.
SHH antibodies, including monoclonal and polyclonal types, are widely used in research to inhibit SHH activity, study pathway mechanisms, or detect SHH expression in tissues. Therapeutically, neutralizing SHH antibodies have been explored to block ligand-receptor interactions in cancers or fibrosis. However, challenges like off-target effects and complex pathway crosstalk limit clinical translation. Some small-molecule inhibitors targeting downstream components (e.g., SMO) are FDA-approved, but antibody-based therapies remain under investigation. These antibodies also serve as diagnostic tools, helping correlate SHH levels with disease progression. Overall, SHH antibodies bridge basic research and therapeutic innovation, though their full potential requires further refinement.
×
